Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| Flexion Therapeutics IncFLXN · Entity 16545 | Director | June 10, 2020 | June 12, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, CFO & CBO | May 11, 2020 | July 10, 2020 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 07, 2022 | June 10, 2022 |
| Vor Biopharma Inc.VOR · Entity 4763 | CFO | December 05, 2025 | December 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Flexion Therapeutics Inc
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 4,500 · Balance 4,500 F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 7,000 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Grant · Acquired 7,000 · Balance 7,000 F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant.
Sarepta Therapeutics, Inc.
Report date May 11, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,260 |
Ending reported balance
After 2020-07-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-05-11 · Gift · Disposed 20,425 · Balance 16,454 F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts. Row 2 · 2020-07-08 · Exercise / conversion · Acquired 2,385 · Balance 18,839 Row 3 · 2020-07-08 · Exercise / conversion · Acquired 218 · Balance 19,057 Row 4 · 2020-07-08 · Exercise / conversion · Acquired 1,203 · Balance 20,260 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-08 · Exercise / conversion · Disposed 2,385 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-08 · Exercise / conversion · Disposed 218 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.63 · Expires 2027-03-10 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-08 · Exercise / conversion · Disposed 1,203 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 12,012 |
Reported balance
Holding disclosure · report date 2020-05-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 12,012 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts.
Spyre Therapeutics, Inc.
Report date June 07, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2032-06-06 | Direct | 43,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 43,000 · Balance 43,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Vor Biopharma Inc.
Report date December 05, 2025 · Filed December 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 694,137 · Balance 0 F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split. F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.80 · Expires 2035-12-04 | Direct | 1,388,274 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Grant · Acquired 1,388,274 · Balance 1,388,274 F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above. F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.
F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.
F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.
F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2017 Filed Aug 7, 2017 20:42 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 6,264 | $37.88 | $237,280.32 |
DisclosureSEC source: 0001209191-17-047901 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,895 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:42 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 13,298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047901 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,500 | $23.85 Strike: $23.85 | $35,775.00 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · derivative · entry 11 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,268 Underlying: Common Stock · 1,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| July 21, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,500 | $23.85 | $35,775.00 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 7,627 | $23.85 Strike: $23.85 | $181,903.95 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,605 Underlying: Common Stock · 7,627 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 32,998 | $13.90 Strike: $13.90 | $458,672.20 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,866 Underlying: Common Stock · 32,998 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 9,375 | $13.71 Strike: $13.71 | $128,531.25 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · derivative · entry 8 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,591 Underlying: Common Stock · 9,375 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 7,627 | $41.00 | $312,707.00 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 6 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,361 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 7,627 | $23.85 | $181,903.95 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 2, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 32,998 | $41.00 | $1,352,918.00 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,361 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 32,998 | $13.90 | $458,672.20 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 9,375 | $41.00 | $384,375.00 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,361 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:49 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,375 | $13.71 | $128,531.25 |
DisclosureSEC source: 0001209191-17-046039 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 18, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2017 Filed Jul 27, 2017 09:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-17-046391 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| March 19, 2017 Filed Mar 21, 2017 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 171 | $30.30 | $5,181.30 |
DisclosureSEC source: 0001209191-17-022109 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,361 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock granted on 9/19/2016. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantIncentive Stock Option (right to buy) · Derivative | 4,751 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020689 · doc4.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,751 Underlying: Common Stock · 4,751 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,749 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020689 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,749 Underlying: Common Stock · 32,749 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:26 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-16-149229 · doc4.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 Underlying: Common Stock · 1,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:26 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,000 | $23.85 | $23,850.00 |
DisclosureSEC source: 0001209191-16-149229 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 30,000 | $13.90 Strike: $13.90 | $417,000.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,874 Underlying: Common Stock · 30,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 30,000 | $50.08 | $1,502,502.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,532 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 30,000 | $13.90 | $417,000.00 |
DisclosureSEC source: 0001209191-16-146354 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on September 15, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 23,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142353 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,532 F2 · shares: 19,125 RSAs vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, with an additional 4,781 RSAs vesting during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:22 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 524 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142353 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Senior Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 F1 · shares: 100% of the Restricted Stock Award ("RSA") granted on September 19, 2016 vests six months from the date of grant. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.